1. G. S. Cooke, M. Lemoine, M. Thursz, et al., Viral hepatitis and the Global Burden of Disease: a need to regroup. J Viral Hepat., vol. 20, no 9, pp. 600-601, 2013.
2. E. Gower, C. Estes, S. Blach, et al., “Global epidemiology and genotype distribution of the hepatitis C virus infection,” J. Hepatol., vol. 61, no. 1, pp. S45–S57, 2014.
3. "WHO Hepatitis C Prevalence 2017" [cited 04.07.2018, 16:55]. Available from:
http://www.who.int/news-room/fact-sheets/detail/hepatitis-c. Published 2017.
4. B. Maasoumy, H. Wedemeyer, “Natural history of acute and chronic hepatitis C,”
https://www.rki.de/DE/Content/Infekt/EpidBull/Merkblaetter/Ratgeber_HepatitisC.
html.
9. Robert-Koch-Institut, “Infektionsepidemiologisches Jahrbuch meldepflichtiger Krankheiten für 2016 (Stand: 1. März 2017),” [cited 14.06.2018, 09:15];
Available from: https://www.rki.de/DE/Content/Infekt/Jahrbuch/Jahrbuch_2016.pdf.
10. D. B. Smith, J. Bukh, C. Kuiken, C. M. Rice, et al.,“Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: Updated criteria and genotype assignment web resource,” Hepatology, vol. 59, no. 1, pp. 318–327, 2014.
11. P. Simmonds, E. C. Holmes, T. A. Cha, et al., “Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region,” J. Gen. Virol., vol. 74, no. 11, pp. 2391–2399, 1993.
12. R. Wasitthankasem, S. Vongpunsawad, N. Siripon, et al., “Genotypic Distribution of Hepatitis C Virus in Thailand and Southeast Asia, ” PLoS One, vol. 10, pp. 1-14, 2015.
13. J. Mellor, E. C. Holmes, L. M. Jarvis, et al., “Investigation of the pattern of hepatitis C virus sequence diversity in different geographical regions: implications for virus classification. The International HCV Collaborative Study Group,” J. Gen. Virol., vol. 76, (pt 10), pp. 2493–2507, 1995.
14. R. S. Ross, S. Viazov, K. Renzing-Köhler, et al., “Changes in the epidemiology of hepatitis C infection in Germany: Shift in the predominance of hepatitis C subtypes",
J. Med. Virol., vol. 60, no. 2, pp. 122–125, 2000.
15. D. B. Smith, S. Pathirana, F. Davidson, et al.,“The origin of hepatitis C virus genotypes.,” J. Gen. Virol., vol. 78 ( Pt 2), pp. 321–328, 1997.
16. A. Ruggieri, C. Arcjentini, et al., “Heterogeneity of hepatitis C virus genotype 2 variants in West Central Africa ( Guinea Conakry ),” J. Gen. Virol., vol. 95, 1996.
54 17. D. Jeannel, C. Fretz, L. Stuyver et al.,“Evidence for high genetic diversity and long-term endemicity of hepatitis C virus genotypes 1 and 2 in West Africa.,” J. Med. Virol., vol. 55, no. 2, pp. 92–97, 1998.
18. H. Tokita, H. Okamoto, F. Tsuda, et al., “Hepatitis C virus variants from Vietnam are classifiable into the seventh, eighth, and ninth major genetic groups,”
ProcNatlAcadSciUSA, vol. 91, no. 23, pp. 11022–11026, 1994.
19. M. J. Alter, “Epidemiology of hepatitis C in the West,” Semin. liver desease, vol. 15, no. 1, pp. 5–14, 1995.
20. J. I. Esteban, S. Sauleda, and J. Quer, “The changing epidemiology of hepatitis C virus infection in Europe.,” J. Hepatol., vol. 48, no. 1, pp. 148–162, Jan. 2008.
21. “European Monitoring Centre for Drugs and Drug Addiction: Annual report 2018: the state of the drugs problem in Europe Luxembourg" [cited 07.11.2018, 11:03];
23. M. Vogt, T. Lang, G. Frösner, et al., “Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening.,” N. Engl. J. Med., vol. 341, pp. 866–870, 1999.
24. M. J. Alter, D. Kruszon-Moran, O. V. Nainan, et al., “The prevalence of hepatitis c virus infection in the United States, 1988 through 1994," N. Engl. J. Med., vol. 341, no.
8, pp. 556–562, 1999.
25. T. C. Hau, J. S. K. Lee, and A. S. F. Lok, “Prevention of posttransfusion hepatitis B and C by screening for antibody to hepatitis C virus and antibody to HBcAg,”
Hepatology, vol. 18, no. 5, pp. 1045–1049, 1993.
26. C. Frank, M. K. Mohamed, G. T. Strickland, et al., “The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt,” Lancet, vol. 355, no. 9207, pp. 887–891, Mar. 2000.
27. S. P. Luby, K. Qamruddin, A. A. Shah, et al., “The relationship between therapeutic injections and high prevalence of hepatitis C infection in Hafizabad, Pakistan.,”
Epidemiol. Infect., vol. 119, no. 3, pp. 349–356, Dec. 1997.
28. D. Hüppe, E. Zehnter, S. Mauss, et al., “[Epidemiology of chronic hepatitis C in Japan.,” Nucleic Acids Res., vol. 17, no. 24, pp. 10367–10372, 1989.
31. Q. L. Choo, K. H. Richman, J. H. Han, et al., “Genetic organization and diversity of the hepatitis C virus.,” Proc. Natl. Acad. Sci. U. S. A., vol. 88, no. 6, pp. 2451–2455, 1991.
32. A. A. Kolykhalov, K. Mihalik, S. M. Feinstone, et al., “Hepatitis C virus-encoded
55 enzymatic activities and conserved RNA elements in the 3’ nontranslated region are essential for virus replication in vivo.,” J. Virol., vol. 74, no. 4, pp. 2046–2051, 2000.
33. B. D. Lindenbach, M. J. Evans, A. J. Syder, et al., “Complete replication of hepatitis C virus in cell culture.,” Science, vol. 309, no. 2005, pp. 623–626, 2005.
34. A. Grakoui, C. Wychowski, C. Lin, et al., “Expression and identification of hepatitis C virus polyprotein cleavage products.,” J. Virol., vol. 67, no. 3, pp. 1385–1395, 1993.
35. M. Hijikata, H. Mizushima, T. Akagi, et al., “Two distinct proteinase activities required for the processing of a putative nonstructural precursor protein of hepatitis C virus.,” J.
Virol., vol. 67, no. 8, pp. 4665–4675, 1993.
36. Y. Miyanari, M. Hijikata, M. Yamaji, et al., “Hepatitis C Virus Non-structural Proteins in the Probable Membranous Compartment Function in Viral Genome Replication,” J.
Biol. Chem., vol. 278, no. 50, pp. 50301–50308, 2003.
37 R. Bartenschlager, L. Ahlborn-Laake, J. Mous, et al., “Nonstructural protein 3 of the hepatitis C virus encodes a serine-type proteinase required for cleavage at the NS3/4 and NS4/5 junctions.,” J. Virol., vol. 67, no. 7, pp. 3835–3844, 1993.
38. S. E. Behrens, L. Tomei, and R. De Francesco, “Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus.,” EMBO J., vol. 15, no. 1, pp.
12–22, 1996.
39. C. Failla, L. Tomei, and R. De Francesco, “Both NS3 and NS4A are required for proteolytic processing of hepatitis C virus nonstructural proteins.,” J. Virol., vol. 68, no. 6, pp. 3753–3760, 1994.
40. C. Lin, B. M. Pragai, and C. M. Rice, “Hepatitis C virus NS3 serine proteinase: trans-cleavage requirements and processing kinetics,” J Virol, vol. 68, no. 12, pp. 8147– virus ( HCV ) NS4B mediates membrane association, correct localization of replication complex proteins, and HCV RNA replication,” J. Virol., vol. 78, no. 20, pp. 11393–
11400, 2004.
43. S. N. Gretton, A. I. Taylor, and J. McLauchlan, “Mobility of the hepatitis C virus NS4B protein on the endoplasmic reticulum membrane and membrane-associated foci,” J. Gen. Virol., vol. 86, no. 5, pp. 1415–1421, 2005.
44. M. G. Katze, B. Kwieciszewski, D. R. Goodlett, et al., “Ser(2194) is a highly conserved major phosphorylation site of the hepatitis C virus nonstructural protein NS5A.,” Virology, vol. 278, no. 2, pp. 501–513, 2000.
45. Y. He, H. Nakao, S.-L. Tan, et al., “Subversion of cell signaling pathways by hepatitis C virus nonstructural 5A protein via interaction with Grb2 and P85 phosphatidylinositol 3-kinase.,” J. Virol., vol. 76, no. 18, pp. 9207–9217, 2002.
46. Z. H. Yuan, U. Kumar, H. C. Thomas, et al., “Expression, purification, and partial characterization of HCV RNA polymerase.,” Biochem. Biophys. Res. Commun., vol.
232, no. 1, pp. 231–235, Mar. 1997.
47. E. Steinmann, F. Penin, T. Pietschmann, et al., “Hepatitis C virus p7 protein is crucial
56 for assembly and release of infectious virions,” PLoS Pathog., vol. 3, no. 7, pp. 0962–
0971, 2007.
48. P. Luik, C. Chew, J. Aittoniemi, et al., “The 3-dimensional structure of a hepatitis C virus p7 ion channel by electron microscopy.,” Proc. Natl. Acad. Sci. U. S. A., vol. 106, no. 31, pp. 12712–12716, 2009.
49. R. Bartenschlager, V. Lohmann, and F. Penin, “The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection.,” Nat. Rev. Microbiol., vol.
11, no. 7, pp. 482–496, 2013.
50. S. Y. Lo, M. J. Selby, and J. H. Ou, “Interaction between hepatitis C virus core protein and E1 envelope protein.,” J. Virol., vol. 70, no. 8, pp. 5177–5182, 1996.
51. M. Kaito, S. Watanabe, K. Tsukiyama-Kohara, et al., “Hepatitis C virus particle detected by immunoelectron microscopic study.,” J.Gen.Virol., vol. 75, no. 1994, pp.
1755–1760, 1994.
52. M. Kaito, S. Watanabe, H. Tanaka, et al., “Morphological identification of hepatitis C virus E1 and E2 envelope glycoproteins on the virion surface using immunogold electron microscopy,” Int. J. Mol. Med., vol. 18, no. 4, pp. 673–678, 2006.
53. S. Takikawa, K. Ishii, H. Aizaki, et al., “Cell fusion activity of hepatitis C virus envelope proteins.,” J. Virol., vol. 74, no. 11, pp. 5066–5074, 2000.
54. E. Scarselli, H. Ansuini, R. Cerino, et al., “The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus.,” EMBO J., vol. 21, no. 19, pp.
5017–5025, 2002.
55. P. Pileri, “Binding of Hepatitis C Virus to CD81,” Science, vol. 282, no. 5390, pp.
938–941, 1998.
56. A. Ploss, M. J. Evans, V. A. Gaysinskaya, et al., “Human occludin is a hepatitis C virus entry factor required for infection of mouse cells,” October, vol. 457, no. 7231, pp. pores.,” Physiology (Bethesda)., vol. 19, no. 6, pp. 331–338, Dec. 2004.
59. S. Molina, V. Castet, C. Fournier-Wirth, et al., “The low-density lipoprotein receptor plays a role in the infection of primary human hepatocytes by hepatitis C virus. Suppl.
Mat,” J. Hepatol., vol. 46, no. 3, pp. 411–419, 2007.
60. C. Voisset, N. Callens, E. Blanchard, et al., “High density lipoproteins facilitate hepatitis C virus entry through the scavenger receptor class B type I,” J. Biol. Chem., vol. 280, no. 9, pp. 7793–7799, 2005.
61. B. Bartosch, A. Vitelli, C. Granier, et al., “Cell entry of hepatitis c virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor,”
J. Biol. Chem., vol. 278, no. 43, pp. 41624–41630, 2003.
62. P. André, F. Komurian-Pradel, S. Deforges, et al., “Characterization of low- and very-low-density hepatitis C virus RNA-containing particles.,” J. Virol., vol. 76, no. 14, pp.
6919–6928, 2002.
63. E. Blanchard, S. Belouzard, L. Goueslain, et al., “Hepatitis C virus entry depends on
57 clathrin-mediated endocytosis.,” J. Virol., vol. 80, no. 14, pp. 6964–6972, 2006.
64. G. Koutsoudakis, A. Kaul, E. Steinmann, et al., “Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses.,” J. Virol., vol. 80, no.
11, pp. 5308–5320, 2006.
65. M. Hsu, J. Zhang, M. Flint, et al., “Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles.,” Proc. Natl. Acad. Sci. U. S.
A., vol. 100, no. 12, pp. 7271–7276, 2003.
66. J. E. Reynolds, A. Kaminski, A. R. Carroll, et al., “Internal initiation of translation of hepatitis C virus RNA: the ribosome entry site is at the authentic initiation codon.,”
RNA (New York, N.Y.), vol. 2, no. 9. pp. 867–878, 1996.
67. N. El-Hage and G. Luo, “Replication of hepatitis C virus RNA occurs in a membrane-bound replication complex containing nonstructural viral proteins and RNA,” J. Gen.
Virol., vol. 84, no. 10, pp. 2761–2769, 2003.
68. D. Egger, B. Wölk, R. Gosert, et al., “Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex.,” J.
Virol., vol. 76, no. 12, pp. 5974–5984, 2002.
69. K. Ogawa, T. Hishiki, Y. Shimizu, et al., “Hepatitis C virus utilizes lipid droplet for production of infectious virus.,” Proc. Jpn. Acad. Ser. B. Phys. Biol. Sci., vol. 85, no. 7, pp. 217–228, 2009.
70. Y. Miyanari, K. Atsuzawa, N. Usuda, et al., “The lipid droplet is an important organelle for hepatitis C virus production.,” Nat. Cell Biol., vol. 9, no. 9, pp. 1089–
1097, 2007.
71. Y. Aizawa, “Chronic hepatitis C virus infection and lipoprotein metabolism,” World J.
Gastroenterol., vol. 21, no. 36, p. 10299, 2015.
72. C. Mancone, C. Steindler, L. Santangelo, et al., “Hepatitis C virus production requires apolipoprotein A-I and affects its association with nascent low-density lipoproteins.,”
Gut, vol. 60, no. 3, pp. 378–386, 2011.
73. B. D. Lindenbach and C. M. Rice, “Unravelling hepatitis C virus replication from genome to function.,” Nature, vol. 436, no. 7053, pp. 933–938, 2005.
74. J. T. Gerlach, H. M. Diepolder, R. Zachoval, et al., “Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance,” Gastroenterology, vol. 125, no. 1, pp. 80–88, Jul. 2003.
75. M. J. Alter, H. S. Margolis, K. Krawczynski, et al., “The natural history of community -acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team.,” N. Engl. J. Med., vol. 327, no. 27, pp. 1899–1905, Dec. 1992.
76. P. Marcellin, “Hepatitis C: the clinical spectrum of the disease.,” J. Hepatol., vol. 31 Suppl 1, pp. 9–16, 1999.
77. A. Maheshwari, S. Ray, and P. J. Thuluvath, “Acute hepatitis C.,” Lancet (London, England), vol. 372, no. 9635, pp. 321–332, Jul. 2008.
78. M. Lehmann, M. F. Meyer, M. Monazahian, et al., “High rate of spontaneous clearance of acute hepatitis C virus genotype 3 infection,” J. Med. Virol., vol. 73, no. 3, pp. 387–
391, 2004.
79. A. E. Yeo, M. Ghany, C. Conry-Cantilena, et al., “Stability of HCV-RNA level and its lack of correlation with disease severity in asymptomatic chronic hepatitis C virus
58 carriers,” J.Viral Hepat., vol. 8, pp. 256–263, 2001.
80. P. Farci, H. J. Alter, A. Shimoda, et al., “Hepatitis C Virus-associated fulminant hepatic failure,” N. Engl. J. Med., vol. 335, no. 9, pp. 631–634, 1996.
81. K. Deterding, N. Grüner, P. Buggisch, et al., “Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial,” Lancet Infect. Dis., vol. 13, no. 6, pp. 497–506, Jun. 2013.
82. M. Wiese, F. Berr, M. Lafrenz, et al., “Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in germany: a 20-year multicenter study.,”
Hepatology, vol. 32, no. 1, pp. 91–96, 2000.
83. S. A. Villano, D. Vlahov, K. E. Nelson, et al., “Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection.,” Hepatology, vol.
29, no. 3, pp. 908–914, 1999.
84. H. J. Alter and L. B. Seeff, “Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome.,” Semin. Liver Dis., vol. 20, no. 1, pp.
17–35, Jan. 2000.
85. H. J. Alter, C. Conry-Cantilena, J. Melpolder, et al., “Hepatitis C in asymptomatic blood donors,” Hepatology, vol. 26, no. 3 Suppl 1, p. 29S–33S, 1997.
86. K. Kiyosawa, Y. Akahane, A. Nagata, et al., “The significance of blood transfusion in non-A, non-B chronic liver disease in Japan.,” Vox Sang., vol. 43, no. 1, pp. 45–52, Jul.
1982.
87. "RKI-Ratgeber - Hepatitis C.” 2016; [cited 02.03.2016, 17:55]; Available from:
http://www.rki.de/DE/Content/Infekt/EpidBull/Merkblaetter/Ratgeber_HepatitisC.html 88. R. Ciria, M. Pleguezuelo, S. E. Khorsandi, et al., “Strategies to reduce hepatitis C virus
recurrence after liver transplantation,” World J. Hepatol., vol. 5, no. 5, pp. 237–250, 2013.
89. M. G. Rumi, F. De Filippi, C. La Vecchia, et al., “Hepatitis C reactivation in patients with chronic infection with genotypes 1b and 2c: a retrospective cohort study of 206 untreated patients.,” Gut, vol. 54, no. 3, pp. 402–406, 2005.
90. T. Poynard, P. Bedossa, and P. Opolon, “Natural history of liver fibrosis progression in patients with chronic hepatitis C,” Lancet, vol. 349, no. 9055, pp. 825–832, Mar. 1997.
91. F. Alborino, A. Burighel, F.-W. Tiller, et al., “Multicenter evaluation of a fully automated third-generation anti-HCV antibody screening test with excellent sensitivity and specificity.,” Med. Microbiol. Immunol., vol. 200, no. 2, pp. 77–83, May 2011.
92. H. J. Alter, R. Sanchez-Pescador, M. S. Urdea, et al., “Evaluation of branched DNA signal amplification for the detection of hepatitis C virus RNA,” J. Viral Hepat., vol. 2, no. 3, pp. 121–132, May 1995.
93. "World Gastroenterology Organisation (WGO) Global Guidelines HCV (long version) 2; [cited 11.11.2018, 12:11]; Available from: http://www.worldgastroenterology.org /UserFiles/file/guidelines/hepatitis-c-english-2017.pdf.
59 pp. 1700–1702, 1998.
96. P. Farci, H. J. Alter, D. Wong, et al., “A long term study of hepatitis C virus replication in Non-a, Non-B Hepatitis,” N. Engl. J. Med., vol. 325, no. 2, pp. 98–104, 1991.
97. J. J. Lefrere, S. Guiramand, F. Lefrere, et al., “Full or partial seroreversion in patients infected by hepatitis C virus.,” J. Infect. Dis., vol. 175, no. 2, pp. 316–322, 1997.
98. S. Iacob, R. Cerban, C. Pietrareanu, et al., “100% sustained virological response and
100. T. Kanda, S. Nakamoto, R. Sasaki, et al., “Sustained Virologic Response at 24 Weeks after the End of Treatment Is a Better Predictor for Treatment Outcome in Real-World HCV-Infected Patients Treated by HCV NS3/4A Protease Inhibitors with Peginterferon plus Ribavirin.“ Int J Med Sci, vol.13, pp. 310-315, 2016.
101. M. G. Swain, M. Lai, M. L. Shiffman, et al., “A Sustained Virologic Response Is Durable in Patients With Chronic Hepatitis C Treated With Peginterferon Alfa-2a and Ribavirin,” Gastroenterology, vol. 139, no. 5, pp. 1593–1601, Nov. 2010.
102. M. Stephanos J. Hadziyannis, Hoel Sette Jr.,et al., “Peginterferon-a2a and Ribavirin Combination Therapy in Chronic Hepatitis C,” Am. Coll. Physicians, vol. 140, no. 5, pp. 346–357, 2004.
103. U. Hopf, B. Möller, V. König, et al., “[Long-term treatment of cryptogenic hepatitis C using recombinant interferon alpha].,” Z. Gastroenterol., vol. 28, no. 9, pp. 453–457, Sep. 1990.
104. P. Glue, R. Rouzier-Panis, C. Raffanel, et al., “A Dose-Ranging Study of Pegylated Interferon Alfa-2b and Ribavirin in Chronic Hepatitis C,” Hepatology, vol. 32, no. 3, pp. 647–653, Sep. 2000.
105. U. S. Karnam and K. R. Reddy, “Pegylated interferons.,” Clin. Liver Dis., vol. 7, no. 1, pp. 139–148, Feb. 2003.
106. C. M. U. Hilkens, J. F. Schlaak, and I. M. Kerr, “Differential Responses to IFN- Subtypes in Human T Cells and Dendritic Cells,” J. Immunol., vol. 171, no. 10, pp.
5255–5263, Nov. 2003.
107. K. L. Lindsay, C. Trepo, T. Heintges, et al., “A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C,” Hepatology, vol. 34, no. 2, pp. 395–403, 2001.
108. J. M. Sánchez Tapias and J. Rodés, “Hepatitis C: who should you treat and how?,”
Blood Purif., vol. 20, no. 1, pp. 124–136, Jan. 2002.
109. “EASL Recommendations on Treatment of Hepatitis C 2015.,” J. Hepatol., vol. 63, no.
1, pp. 199–236, Apr. 2015.
110. P. D’Innella, G. Zaccala, M. Terazzi, et al., “[Psychotic disorders induced by interferon alfa].,” Recenti Prog. Med., vol. 93, no. 6, pp. 367–369, Jun. 2002.
111. F. Poordad, J. McCone, B. R. Bacon, et al., “Boceprevir for untreated chronic HCV genotype 1 infection.,” N. Engl. J. Med., vol. 364, no. 13, pp. 1195–1206, Mar. 2011.
112. J. G. McHutchison, G. T. Everson, S. C. Gordon, et al., “Telaprevir with peginterferon
60 and ribavirin for chronic HCV genotype 1 infection.,” N. Engl. J. Med., vol. 360, no.
18, pp. 1827–1838, Apr. 2009.
113. I. M. Jacobson, J. G. McHutchison, G. Dusheiko, et al., “Telaprevir for previously untreated chronic hepatitis C virus infection.,” N. Engl. J. Med., vol. 364, no. 25, pp.
2405–2416, Jun. 2011.
114. J.-M. Pawlotsky and E. Al, “EASL Recommendations on Treatment of Hepatitis C 2014,” ILC 2014 London, vol. 63, pp. 199–236, 2014.
115. P. Y. Kwo, E. J. Lawitz, J. McCone, et al., “Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial.,” Lancet (London, England), vol. 376, no. 9742, pp. 705–716, Aug. 2010.
116. M. Charlton, G. T. Everson, S. L. Flamm, et al., “Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease.,”
Gastroenterology, vol. 149, no. 3, pp. 649–659, Sep. 2015.
117. N. Hayashi, N. Izumi, H. Kumada, et al., “Simeprevir with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial.,” J. Hepatol., vol. 61, no. 2, pp. 219–227, Aug. 2014.
118. G. J. Dore, E. Lawitz, C. Hézode, et al., “Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection.,” Gastroenterology, vol. 148, no. 2, pp. 355–
366.e1, Feb. 2015.
119. N. Afdhal, S. Zeuzem, P. Kwo, et al., “Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection,” N. Engl. J. Med., vol. 370, no. 20, pp. 1889–1898, May 2014.
120. M. S. Sulkowski, D. F. Gardiner, M. Rodriguez-Torres, et al., “Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.,” N. Engl. J.
Med., vol. 370, no. 3, pp. 211–221, Jan. 2014.
121. K. Bichoupan, N. Tandon, V. Martel-Laferriere, et al., “Factors associated with success of telaprevir- and boceprevir-based triple therapy for hepatitis C virus infection.,”
World J. Hepatol., vol. 9, no. 11, pp. 551–561, Apr. 2017.
122. DGVS, “Aktuelle Empfehlung zur Therapie der chronischen HCV,” 2016;
[cited 02.01.2017, 13:03]; Available from:https://www.dgvs.de/wissen-kompakt/leitlinien/leitlinien-der-dgvs/hepatitis-c/.
123. C. Yek, C. de la Flor, J. Marshall, et al., “Effectiveness of direct-acting antiviral therapy for hepatitis C in difficult-to-treat patients in a safety-net health system: A retrospective cohort study,” BMC Med., vol. 15, no. 1, pp. 1–8, 2017.
124. T. Asselah, S. Bourgeois, S. Pianko, et al., “Sofosbuvir/Velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosis,” Liver Int., February, pp. 1–8, 2017.
125. J. J. Feld, I. M. Jacobson, C. Hézode, et al., “Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection,” N. Engl. J. Med., vol. 373, no. 27, pp. 2599–
2607, Dec. 2015.
126. R. B. Perumpail, “Treatment strategies for chronic hepatitis C prior to and following liver transplantation,” World J. Hepatol., vol. 8, no. 1, p. 69, 2016.
61 127. G. P. Györi, G. R. Silberhumer, A. Rahmel, et al., “Impact of dynamic changes in meld
score on survival after liver transplantation - a eurotransplant registry analysis,” Liver Int., p. 1011–1017, 2016.
128. M. Garcia-Retortillo, X. Forns, A. Feliu, et al., “Hepatitis C virus kinetics during and immediately after liver transplantation,” Hepatology, vol. 35, no. 3, pp. 680–687, 2002.
129. M. Berenguer, M. Prieto, F. S. Juan, et al., “Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients,”
Hepatology, vol. 36, no. 1, pp. 202–210, 2002.
130. M. Prieto, M. Berenguer, J. M. Rayón, et al., “High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: Relationship with rejection episodes,” Hepatology, vol. 29, no. 1, pp. 250–256, 1999.
131. S. J. Pelletier, D. P. Raymond, T. D. Crabtree, et al., “Pretransplantation hepatitis C virus quasispecies may be predictive of outcome after liver transplantation,”
Hepatology, vol. 32, no. 2, pp. 375–381, 2000.
132. C. Vinaixa, A. Rubín, V. Aguilera, and M. Berenguer, “Recurrence of hepatitis C after liver transplantation.,” Ann. Gastroenterol., vol. 26, no. 4, pp. 304–313, 2013.
133. J. A. Carrión, M. Navasa, M. García–Retortillo, et al., “Efficacy of Antiviral Therapy on Hepatitis C Recurrence After Liver Transplantation: A Randomized Controlled Study,” Gastroenterology, vol. 132, no. 5, pp. 1746–1756, May 2007.
134. G. T. Everson, N. A. Terrault, A. S. Lok, et al., “A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation.,” Hepatology, vol. 57, no. 5, pp. 1752–1762, May 2013.
135. C. Féray, M. Gigou, D. Samuel, et al., “Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease after liver transplantation,” Gastroenterology, vol. 108, no 4, pp. 96-1088, 1995.
136. H. E. Vargas, T. Laskus, L. F. Wang, et al., “The influence of hepatitis C virus genotypes on the outcome of liver transplantation,” Liver Transpl Surg, vol. 4, no. 1, pp. 22–27, 1998.
137. S. Zhou, N. A. Terrault, L. Ferrell, et al., “Severity of liver disease in liver transplantation recipients with hepatitis C virus infection: Relationship to genotype and level of viremia,” Hepatology, vol. 24, no. 5, pp. 1041–1046, 1996.
138. M. Berenguer, V. Aguilera, M. Prieto, et al., “Worse recent efficacy of antiviral therapy in liver transplant recipients with recurrent hepatitis C: impact of donor age and baseline cirrhosis.,” Liver Transpl., vol. 15, no. 7, pp. 738–746, Jul. 2009.
139. B. Cieślak, Z. Lewandowski, M. Urban, et al., “Microvesicular Liver Graft Steatosis as a Risk Factor of Initial Poor Function in Relation to Suboptimal Donor Parameters,”
Transplantation Proceedings, vol.41, no 8, pp 2985-2988, Oct 2009.
140. J. M. Langrehr, G. Puhl, M. Bahra, et al., “Influence of donor/recipient HLA-matching on outcome and recurrence of hepatitis C after liver transplantation.,” Liver Transpl., vol. 12, no. 4, pp. 644–651, Apr. 2006.
141. R. Gedaly, T. M. Clifford, P. P. McHugh, et al., “Prevalent immunosuppressive strategies in liver transplantation for hepatitis C: Results of a multi-center international survey,” Transpl. Int., vol. 21, no. 9, pp. 867–872, 2008.
142. T. E. Starzl and S. Iwatsuki, “Report of Colorado-Pittsburgh Liver Transplantation
62 Studies,” Transpl. Proc., vol. 15, no. 4, pp. 2582–2585, 1983.
143. S. Steiner, C. Daniel, A. Fischer, et al., “Cyclosporine a regulates pro-inflammatory cytokine production in ulcerative colitis,” Arch. Immunol. Ther. Exp. (Warsz)., vol. 63, no. 1, pp. 53–63, 2014.
144. B. K. Krämer, D. Del Castillo, R. Margreiter, et al., “Efficacy and safety of tacrolimus compared with ciclosporin a in renal transplantation: Three-year observational results,”
Nephrol. Dial. Transplant., vol. 23, no. 7, pp. 2386–2392, 2008.
145. S. Ciesek, E. Steinmann, H. Wedemeyer, et al., “Cyclosporine A inhibits hepatitis C virus nonstructural protein 2 through cyclophilin A.,” Hepatology, vol. 50, no. 5, pp.
1638–1645, 2009.
146. S. Marubashi, K. Dono, H. Nagano, et al. “Steroid-free living donor liver transplantation in adults: Impact on hepatitis C recurrence,” Clin. Transplant., vol. 23, no. 6, pp. 904–913, 2009.
147. G. Sgourakis, A. Radtke, I. Fouzas, et al., “Corticosteroid-free immunosuppression in liver transplantation: A meta-analysis and meta-regression of outcomes,” Transpl. Int., vol. 22, no. 9, pp. 892–905, 2009.
148. F. S. Juan, M. Berenguer, V. Aguilera, et al., “Significant improvement in the outcome
148. F. S. Juan, M. Berenguer, V. Aguilera, et al., “Significant improvement in the outcome